Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Invested Capital (2022 - 2025)

Historic Invested Capital for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$72.1 million.

  • BioXcel Therapeutics' Invested Capital fell 44548.59% to -$72.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$72.1 million, marking a year-over-year decrease of 44548.59%. This contributed to the annual value of $13.6 million for FY2024, which is 7049.94% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Invested Capital stood at -$72.1 million for Q3 2025, which was down 44548.59% from -$96.5 million recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Invested Capital high stood at $234.3 million for Q2 2022, and its period low was -$96.5 million during Q2 2025.
  • In the last 4 years, BioXcel Therapeutics' Invested Capital had a median value of $46.2 million in 2023 and averaged $70.4 million.
  • Its Invested Capital has fluctuated over the past 5 years, first crashed by 1955.73% in 2023, then plummeted by 44548.59% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Invested Capital stood at $178.2 million in 2022, then tumbled by 74.09% to $46.2 million in 2023, then crashed by 70.5% to $13.6 million in 2024, then tumbled by 629.3% to -$72.1 million in 2025.
  • Its Invested Capital stands at -$72.1 million for Q3 2025, versus -$96.5 million for Q2 2025 and -$84.6 million for Q1 2025.